Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation

Acta Pharmaceutica Sciencia

Volumn 52, Issue 3, 2010, Pages 305-314

  Nakarani, Mahendra ^a   Misra, Ambikanandan ^b   Patel, Jayvadan ^c   Vaghani, Subhash ^d  

^a Unison pharmaceuticals   (India)

^b M S UNIVERSITY OF BARODA   (India)

^c NOOTAN PHARMACY COLLEGE   (India)

^d Smt R B Patel Mahila Pharmacy College   (India)

Author keywords

Itraconazole; Nanosuspension; Pearl milling technique

Indexed keywords

CANDITRAL CAPSULE; GLYCEROL; ITRACONAZOLE; POLOXAMER; UNCLASSIFIED DRUG; ZIRCONIUM OXIDE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MARKETING; DRUG SOLUBILITY; IN VITRO STUDY; NANOSUSPENSION; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SUSPENSION; X RAY DIFFRACTION;

EID: 79751491509     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Amidon, G.L., Lennernas, H., Shah, V.P. and Crison, J.R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailablility. Pharm. Res. 12: 413-420.
2. Barratt, G.M. (2000). Therapeutic applications of colloidal drug carriers. Pharm. Sci. Tech. Today. 3: 163-169.
3. Chiba, Y., Kohri, N., Iseki, K. and Miyazaki, K. (1991). Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. Chem. Pharm. Bull. 39: 2158-2160.
4. Fromtling, R.A. (1987). Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. J.R. Prous Science Publishers, Barcelona, Spain, pp. 233-249.
5. Guo, J., Ping, Q. and Chen, Y. (2001). Pharmacokinetic behavior of Cyclosporine A in rabbits by oral administration of lecithin vesicle and sandimmun neoral. Int. J. Pharm. 216: 17-21.
6. Liversidge, M.E., Sarpotdar, P., Bruno, J., Hajj, S. and Wel, L. (1996). Formulation and antitumor evaluation of nano crystalline suspensions of poorly soluble anticancer drug. Pharm. Res. 13: 272-278.
7. Maeda, T., Takenaka, H., Yamahira, Y. and Noguchi, T. (1979). Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets. J. Pharm. Sci. 68: 1286-1289.
8. Muller, R.H. (1991). In vivo distribution of carriers. In Colloidal Carriers for Controlled Drug Delivery and Targeting. CRC Press inc. Boca Raton, FL. pp. 211-274.
9. Muller, R.H. and Jacobs, C. (2002). Buparvaquone mucoadhesive nanosuspension: preparation, optimization and long-term stability. Int. J. Pharm. 237: 151-161.
10. Muller, R.H. and Peters, K. (1997). Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int. J. Pharm. 160: 229-237.
11. Muller, R.H., Jacobs, C. and Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 47: 3-19.
12. Odds, F.C., Oris, M., Dorsselaer, P.V. and Gerven, F.V. (2000). Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob. Agents. Chemother. 44: 3180-3183.
13. Saag, M.S. and Dismukes, W.E., (1988). Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents. Chemother. 32: 1-8.
14. Teeranachaideekul, V., Junyaprasert, V.B., Souto, E.B. and Muller, R.H. (2008). Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 354: 227-234
15. Westesen, K. and Siekmann, B. (1995). Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharm. Res. 12: 201-208.